Literature DB >> 15917102

Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.

Olga Pletnikova1, Neva West, Michael K Lee, Gay L Rudow, Richard L Skolasky, Ted M Dawson, Laura Marsh, Juan C Troncoso.   

Abstract

In order to understand better the neuropathological substrate of dementia in Parkinson's disease (PD) and to examine its interactions with Alzheimer's disease (AD), we examined autopsy brains from 21 cases of PD and Lewy body disease (LBD) with dementia. We separated brains in two groups according to the presence of Abeta deposits. In brains without Abeta, we found few or no Lewy bodies (LB) in the cerebral cortex. By contrast, in brains with Abeta, we observed significant increases in LB in the cerebral cortex (p < 0.01) and alpha-synuclein immunoreactive lesions in the cingulate cortex (p < 0.01). Immunoblots of alpha-synuclein from cingulate cortex in brains with Abeta showed significantly higher levels of insoluble alpha-synuclein compared to brains without Abeta. Our observations indicate that in cases of PD with dementia, the neocortex is not necessarily involved by LB. Furthermore, the presence of Abeta deposits in the cerebral cortex was associated with extensive alpha-synuclein lesions and higher levels of insoluble alpha-synuclein. This suggests that Abeta enhances the development of cortical alpha-synuclein lesions in cases of PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15917102     DOI: 10.1016/j.neurobiolaging.2004.10.006

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  64 in total

1.  Amyloid imaging of Lewy body-associated disorders.

Authors:  Erin R Foster; Meghan C Campbell; Michelle A Burack; Johanna Hartlein; Hubert P Flores; Nigel J Cairns; Tamara Hershey; Joel S Perlmutter
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

3.  An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology.

Authors:  Christian Wider; Owen A Ross; Kenya Nishioka; Michael G Heckman; Carles Vilariño-Güell; Barbara Jasinska-Myga; Nilufer Erketin-Taner; Rosa Rademakers; Neill R Graff-Radford; Deborah C Mash; Spiridon Papapetropoulos; Ranjan Duara; Hirotake Uchikado; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-01-30       Impact factor: 10.154

4.  Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Alexander M Herman; G William Rebeck; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2011-09-14       Impact factor: 4.314

Review 5.  Inflammation in the early stages of neurodegenerative pathology.

Authors:  Preeti J Khandelwal; Alexander M Herman; Charbel E-H Moussa
Journal:  J Neuroimmunol       Date:  2011-08-05       Impact factor: 3.478

6.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

7.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

8.  From model system to clinical medicine: pathophysiologic links of common proteinopathies.

Authors:  Pamela J McMillan; James B Leverenz
Journal:  Alzheimers Res Ther       Date:  2010-09-17       Impact factor: 6.982

9.  Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation.

Authors:  Miguel A Riudavets; Leonardo Bartoloni; Juan C Troncoso; Olga Pletnikova; Peter St George-Hyslop; Marcelo Schultz; Gustavo Sevlever; Ricardo F Allegri
Journal:  Brain Pathol       Date:  2013-04-25       Impact factor: 6.508

10.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.